Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT04925141
- Locations
- 🇨🇳
The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China
🇨🇳Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Affiliated Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04924192
- Locations
- 🇨🇳
The Second Affiliated Hospital of PLA Air Force Military Medical University, Xi'an, Shanxi, China
🇨🇳Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
🇨🇳West China Hospital of Sichuan University, Chengdou, Sichuan, China
Phase I Clinical Trial of TQC2731 Injection
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT04923607
- Locations
- 🇨🇳
First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, China
A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04895345
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Hospital, Guangzhou, Guangdong, China
Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04854681
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 748
- Registration Number
- NCT04854668
- Locations
- 🇨🇳
The First Affiliated Hospital of ZhengZhou University, Zhengzhou, Henan, China
🇨🇳Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
🇨🇳Changzhi People's Hospital, Changzhi, Shanxi, China
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04853498
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04836663
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳Sir Run Run Shaw Hospital Medical School Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04827004
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT04808570
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliate Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China